FDA’s assessment of potential bioequivalence and therapeutic equivalence problems with generic extended-release metoprolol products shows that the agency appears to be settling into a pattern for investigating these kinds of concerns, but is not using a single fixed script each time.
“Therapeutic inefficacy and adverse events have been reported by physicians and patients switching from brand to generic metoprolol extended release products,” FDA said in a